This is a summary of the European public assessment report (EPAR) for Sialanar. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Sialanar. For practical information about using Sialanar, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.
Therapeutic Area (MeSH)
ATC Code
A03AB02
ATC Item
glycopyrronium bromide
Pharmacotherapeutic Group
Drugs for functional gastrointestinal disorders
Active Substance (Summary)
INN / Common Names
EMA Name
Sialanar
Medicine Name
Sialanar
Aliases
N/ANo risk management plan link.
